PharmAla Files Preliminary Base Shelf Prospectus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 20 2025
0mins
Source: Globenewswire
Prospectus Filing: PharmAla Biotech Holdings Inc. has filed a preliminary short form base shelf prospectus to raise up to C$50 million through the sale of various securities over a 25-month period, allowing flexibility for future financing opportunities.
Company Overview: PharmAla focuses on the research and development of MDXX class molecules, including MDMA, and aims to alleviate the backlog of clinical-grade MDMA while developing novel drugs in the same category.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
